Skip to main content
To the Editor: ECT is a treatment of red lines. There was once a red line against its use even in consenting adults, stemming mainly from the antipsychiatry movement of the 1960s and the impact of Hollywood movies (1). Despite enduring stigma, ECT is now available for adults in most states, although significant variations in usage remain (2).
Yet, a second red line remains in effect for minors and individuals with developmental disabilities. In the early days, administering treatments to adolescents and even children was commonplace. But ECT in the pediatric population likewise became stigmatized, and it remains widely rejected despite solid evidence of its efficacy and safety in these patients. In particular, there is a substantial literature on the dramatic benefits of ECT in treating severe affective, psychotic, and catatonic disturbances. A case report describing the alleviation of intractable repetitive self-injurious behavior causing profound bodily damage in an autistic girl with concomitant catatonia was presented in the Journal in 2008 (3).
Restricted access to ECT for all who need it, regardless of age, race, disability, socioeconomic status, or geographical location constitutes an important ethical problem. We are keenly aware that many individuals with affective and behavioral disturbances that respond exquisitely to convulsive therapy, especially children and the intellectually disabled, do not have equal access to it.
The reasons are manifold: insufficient institutional resources and trained specialists, arbitrary prohibitions, and the prevailing view of ECT as a treatment of last resort. Inhibiting regulations dot the American landscape, regulations that affect no other accepted medical intervention. ECT is prohibited for children under age 12 in California and under age 16 in Colorado and Texas; requires court approval for minors in Illinois, Michigan, and Tennessee; and requires independent ethics board approval in New York (4).
It is unclear how many patients are affected by these ill-justified restrictions. No current literature documents the number of U.S. patients with ECT-responsive pathology denied access to treatment, nor patients for whom approval was not sought because of administrative and legal barriers. It may be argued that the situation is comparatively rare. Yet equality of access demands the attention of the larger psychiatric community, not because of the numbers involved but because treatment is so simple. ECT in children, adolescents, and patients with concurrent developmental disability can be life-saving; that it is denied for unscientific reasons is a challenge to the ethical principles of medical care and should be of concern to all practitioners, not just those in the trenches of care for these special populations.

References

1.
Shorter E, Healy D: Shock Therapy: A History of Electroconvulsive Treatment in Mental Illness. New Brunswick, NJ, and London, Rutgers University Press, 2007
2.
Fink M: Electroshock: Restoring the Mind. New York, Oxford University Press, 1999
3.
Wachtel LE, Kahng SW, Dhossche DM, Cascella N, Reti IM: ECT for catatonia in an autistic girl. Am J Psychiatry 2008; 165:329–333
4.
Winslade WJ, Liston EH, Ross JW, Weber KD: Medical, judicial, and statutory regulation of ECT in the United States. Am J Psychiatry 1984; 141:1349–1355

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1498 - 1499
PubMed: 24306344

History

Accepted: September 2013
Published online: 1 December 2013
Published in print: December 2013

Authors

Details

Lee E. Wachtel, M.D.
From the Department of Psychiatry, Kennedy Krieger Institute, Baltimore; the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Miss.; the Department of Psychiatry and Neurology, SUNY at Stony Brook, Stony Brook, N.Y.; the Department of Psychiatry, Einstein Medical Center, Philadelphia; the Department of Psychiatry, Mount Sinai School of Medicine, New York; the Department of Psychiatry, University of Utah, Salt Lake City; and Faculty of Medicine, History of Medicine Program, University of Toronto, Ontario.
Dirk M. Dhossche, M.D.
From the Department of Psychiatry, Kennedy Krieger Institute, Baltimore; the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Miss.; the Department of Psychiatry and Neurology, SUNY at Stony Brook, Stony Brook, N.Y.; the Department of Psychiatry, Einstein Medical Center, Philadelphia; the Department of Psychiatry, Mount Sinai School of Medicine, New York; the Department of Psychiatry, University of Utah, Salt Lake City; and Faculty of Medicine, History of Medicine Program, University of Toronto, Ontario.
Max Fink, M.D.
From the Department of Psychiatry, Kennedy Krieger Institute, Baltimore; the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Miss.; the Department of Psychiatry and Neurology, SUNY at Stony Brook, Stony Brook, N.Y.; the Department of Psychiatry, Einstein Medical Center, Philadelphia; the Department of Psychiatry, Mount Sinai School of Medicine, New York; the Department of Psychiatry, University of Utah, Salt Lake City; and Faculty of Medicine, History of Medicine Program, University of Toronto, Ontario.
Richard Jaffe, M.D.
From the Department of Psychiatry, Kennedy Krieger Institute, Baltimore; the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Miss.; the Department of Psychiatry and Neurology, SUNY at Stony Brook, Stony Brook, N.Y.; the Department of Psychiatry, Einstein Medical Center, Philadelphia; the Department of Psychiatry, Mount Sinai School of Medicine, New York; the Department of Psychiatry, University of Utah, Salt Lake City; and Faculty of Medicine, History of Medicine Program, University of Toronto, Ontario.
Charles H. Kellner, M.D.
From the Department of Psychiatry, Kennedy Krieger Institute, Baltimore; the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Miss.; the Department of Psychiatry and Neurology, SUNY at Stony Brook, Stony Brook, N.Y.; the Department of Psychiatry, Einstein Medical Center, Philadelphia; the Department of Psychiatry, Mount Sinai School of Medicine, New York; the Department of Psychiatry, University of Utah, Salt Lake City; and Faculty of Medicine, History of Medicine Program, University of Toronto, Ontario.
Howard Weeks, M.D.
From the Department of Psychiatry, Kennedy Krieger Institute, Baltimore; the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Miss.; the Department of Psychiatry and Neurology, SUNY at Stony Brook, Stony Brook, N.Y.; the Department of Psychiatry, Einstein Medical Center, Philadelphia; the Department of Psychiatry, Mount Sinai School of Medicine, New York; the Department of Psychiatry, University of Utah, Salt Lake City; and Faculty of Medicine, History of Medicine Program, University of Toronto, Ontario.
Edward Shorter, Ph.D.
From the Department of Psychiatry, Kennedy Krieger Institute, Baltimore; the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Miss.; the Department of Psychiatry and Neurology, SUNY at Stony Brook, Stony Brook, N.Y.; the Department of Psychiatry, Einstein Medical Center, Philadelphia; the Department of Psychiatry, Mount Sinai School of Medicine, New York; the Department of Psychiatry, University of Utah, Salt Lake City; and Faculty of Medicine, History of Medicine Program, University of Toronto, Ontario.

Competing Interests

Dr. Jaffe has served on the speakers bureau for Merck and Otsuka and has consulted for Alexza Pharmaceuticals. Dr. Kellner has received honoraria from UpToDate, Psychiatric Times, Cambridge University Press, and Northshore–Long Island Jewish Health System and grant support from NIMH. Drs. Wachtel and Fink report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share